ValuEngine upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a strong sell rating to a sell rating in a report published on Wednesday morning.
ICPT has been the topic of several other reports. Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 12th. They set a buy rating and a $106.00 price target on the stock. Credit Suisse Group set a $167.00 price objective on shares of Intercept Pharmaceuticals and gave the company a buy rating in a research report on Monday, January 22nd. BidaskClub lowered shares of Intercept Pharmaceuticals from a sell rating to a strong sell rating in a research report on Tuesday, January 16th. Wedbush reissued a buy rating and issued a $253.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, January 5th. Finally, Citigroup set a $74.00 price objective on shares of Intercept Pharmaceuticals and gave the company a hold rating in a research report on Friday, December 29th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $128.75.
NASDAQ ICPT opened at $71.60 on Wednesday. The company has a debt-to-equity ratio of 21.71, a quick ratio of 4.31 and a current ratio of 4.31. Intercept Pharmaceuticals has a 1 year low of $51.05 and a 1 year high of $135.59. The firm has a market cap of $1,802.39, a price-to-earnings ratio of -4.98 and a beta of -1.82.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative return on equity of 267.95% and a negative net margin of 275.18%. The firm had revenue of $37.69 million for the quarter, compared to the consensus estimate of $39.01 million. During the same period last year, the company posted ($4.84) earnings per share. The business’s revenue was up 173.1% compared to the same quarter last year. equities research analysts anticipate that Intercept Pharmaceuticals will post -12.6 EPS for the current year.
Large investors have recently added to or reduced their stakes in the stock. DSC Advisors L.P. bought a new position in Intercept Pharmaceuticals during the fourth quarter worth about $204,000. Amalgamated Bank bought a new position in Intercept Pharmaceuticals during the fourth quarter worth about $209,000. Virtu Financial LLC bought a new position in Intercept Pharmaceuticals during the fourth quarter worth about $234,000. Wedbush Securities Inc. bought a new position in Intercept Pharmaceuticals during the fourth quarter worth about $331,000. Finally, Teacher Retirement System of Texas bought a new position in Intercept Pharmaceuticals during the fourth quarter worth about $346,000. 74.27% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/intercept-pharmaceuticals-icpt-stock-rating-upgraded-by-valuengine.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.